De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression.

Naveen Kumar Tangudu Raquel Buj Hui Wang Jiefei Wang Aidan R Cole Apoorva Uboveja Richard Fang Amandine Amalric Baixue Yang Adam Chatoff Claudia V Crispim Peter Sajjakulnukit Maureen A Lyons Kristine L Cooper Nadine Hempel Costas Andreas Lyssiotis Uma R Chandran Nathaniel W Snyder Katherine Marie Aird

Published in: Cancer research communications (2024)

Antimetabolites were the first chemotherapies, yet many have failed in the clinic due to toxicity and poor patient selection. Our data suggest that p16 loss provides a therapeutic window to kill cancer cells with widely-used antifolates with relatively little toxicity.

Keyphrases

oxidative stress
poor prognosis
climate change
primary care
case report
electronic health record
oxide nanoparticles
binding protein